KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EBITDA (2016 - 2025)

Historic EBITDA for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Vertex Pharmaceuticals' EBITDA rose 626.18% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 157684.91%. This contributed to the annual value of -$232.9 million for FY2024, which is 10607.78% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' EBITDA is $1.2 billion, which was up 626.18% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' EBITDA registered a high of $1.2 billion during Q3 2025, and its lowest value of -$3.5 billion during Q2 2024.
  • Moreover, its 5-year median value for EBITDA was $1.0 billion (2022), whereas its average is $718.7 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' EBITDA surged by 301899.74% in 2022 and then crashed by 44242.99% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' EBITDA (Quarter) stood at $877.7 million in 2021, then rose by 17.75% to $1.0 billion in 2022, then decreased by 4.35% to $988.5 million in 2023, then increased by 3.79% to $1.0 billion in 2024, then increased by 15.61% to $1.2 billion in 2025.
  • Its EBITDA was $1.2 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $630.1 million in Q1 2025.